Longevity, Demystified: A Q&A with Phil Newman, Founder & CEO of Longevity.Technology

Last week, I shared a few key insights from my conversation with Dr Avi Roy during the Founders Longevity Forum Singapore.

In addition to that inspiring dialogue, I had the pleasure of sitting down with Phil Newman , Founder and CEO of Longevity.Technology After more than 20 years leading an international commercialisation consultancy, Phil founded Longevity.Technology—a platform that has become a leading voice in the longevity space, connecting science, investment, and consumer interest in a way that’s both credible and accessible.

We spoke about the evolving landscape of longevity science, what’s next for the industry, and how we can all better engage with the tools that will shape our healthspan.

Here’s what we discussed:

Q: As a leader in the longevity technology space, how do you see the role of media and platforms like Longevity.Technology in educating the public about the practical applications of longevity medicine?

Phil: Media plays a pivotal role in demystifying longevity medicine. At Longevity.Technology, we ensure that evidence-based information is presented clearly, responsibly, and accessibly. Given our diverse audience – ranging from consumers to clinicians and investors – we take editorial rigour seriously.

We break down complex scientific topics like biomarkers, epigenetics, and cellular rejuvenation into digestible content, making it easier for people to understand how longevity science applies to their daily lives and health decisions. It’s all about building longevity literacy.

Q: You’ve seen rapid growth in various sectors of the longevity industry. Where do you believe we’re heading next? Will the future be defined more by supplements, clinics, or cutting-edge tech like AI and gene therapies?

Phil: We see longevity progressing through three phases:

1. Longevity 1.0: The current phase, which includes supplements, diagnostics, clinics, and biohacking. People are beginning to understand that ageing is flexible, not fixed. Tools like TrDiagnostic and GlycanAge, and clinics offering personalised interventions, are gaining global traction.

2. Longevity 2.0: This is the biotech wave. Think GLP-1 agonists that are already making strides in treating diabetes and cardiovascular issues. Once longevity-specific drugs are approved, we’ll see an inflection point in public health and investor interest.

3. Longevity 3.0: The future. This is where AI meets biology – potentially even the digitisation of human consciousness. It’s speculative now, but the groundwork is being laid. The future will look very different.

Q: How do you envision the future of longevity in your field? What are the biggest challenges and opportunities?

Phil: We track 25 domains across longevity science, and while investment is growing – doubling to $8.3B in 2024 – we need more capital flowing into research and innovation. We see this as a core mission for Longevity.Technology and will be making a big announcement on this soon.

Standardising ageing biomarkers is another critical challenge. Without a common set of metrics, it’s harder to unify clinical research and regulatory pathways. The Biomarkers of Aging Consortium is making important strides in this space.

Opportunities lie in leveraging AI-driven diagnostics and predictive tools to personalise 

health strategies while expanding public awareness through platforms like Longevity.Technology.

Q: What common misconceptions or myths about longevity would you like to see debunked?

Phil: I believe the biggest misconception is that longevity is just about living longer. That’s not the goal. It’s about healthspan – living more years in good health, free from chronic disease.

Another myth is the belief in quick fixes – detox diets, miracle pills and magic potions. In reality, effective ageing strategies are grounded in science: balanced nutrition, exercise, stress management, and interventions that have undergone human trials.

Q: What advice would you give to someone who wants to improve their healthspan but doesn’t know where to start?

Phil: Start with data-driven insights into your health. Simple tools like smart scales offer insights into metabolic health. Genomic testing can flag deficiencies or genetic predispositions to diseases for early intervention, while longevity clinics provide in-depth analysis across physical and mental health.

We launched www.FLT.life for this very reason. Our three supplements – Longevity, Muscle, and Cognition – are grounded in human data and all contain ingredients validated in studies that demonstrate efficacy in managing age-related decline. We also partnered with TruDiagnostic to help users measure biological age and track how these supplements, when combined with lifestyle changes, can slow the pace of ageing.

To summarise, it’s about personal empowerment through reliable information and tailored action.